Give her effective vaginal atrophy treatment with Blissel

Blissel® is an effective treatment for postmenopausal women with VA.1,2

Please refer to safety information below.

Blissel allows you to treat vaginal atrophy whilst limiting systemic exposure to estrogens

Low dose estriol formulations, such as Blissel, have significantly lower systemic absorption than higher dose medications.3

Blissel® is an effective treatment for postmenopausal women with VA.1,2

Please refer to safety information below.

Blissel allows you to treat vaginal atrophy whilst limiting systemic exposure to estrogens

Low dose estriol formulations, such as Blissel, have significantly lower systemic absorption than higher dose medications.3

Safety and Precautions2

  • For the treatment of postmenopausal vaginal atrophy symptoms, local estrogen therapy should only be initiated for symptoms that adversely affect quality of life.
  • Blissel 50 micrograms/g vaginal gel must not be combined with estrogen preparations for systemic treatment, as there are no studies of safety and risks with estrogen concentrations attained in combination treatment.
  • Intravaginal applicator may cause minor local trauma, especially in women with serious vaginal atrophy.
  • Before estriol treatment is initiated or reinstituted, a complete personal and family medical history should be taken. Physical (including pelvic and breast) examination should be guided by this and by the contraindications and warnings for use.

Please refer to the Summary of Product Characteristics before prescribing.2

Common (1/100 to <1/10) and uncommon (1/1000 to <1/100) undesirable effects2

Prescribing and adverse event reporting information can be found at the end of this video.

Blissel works quickly

Blissel is effective for treating vaginal dryness

which improves or completely resolves in over 88% of women.1*

*vs placebo, P=0.001; relative risk [RR], 1.32; CI, 1.08-1.62.

Blissel significantly improves changes due to vaginal atrophy1:

Prescribing and adverse event reporting information can be found at the end of this video.

Administration

Blissel can be administered by the patient using the included applicator2

Ensuring that the process is comfortable and mess-free.

Release her confidence from within.

To book a visit from a Consilient Health Blissel trained healthcare manager, please click here to complete our DATA compliant form:

Vaginal

Atrophy

How Blissel

Works

Dosing

Ultra low dose estriol vaginal gel1,2

Prescribing and Adverse event reporting information for Blissel can be found here.

 Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com 

  1. Cano A, et al. Menopause. 2012;19(10):1130-9. 2. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics. 3. Delgado JL, et al. Climacteric. 2016;19(2):172-80.

Date of preparation: Feb 2026 | UK-BLS-43d(5)

CLOSE X


  • For the treatment of postmenopausal vaginal atrophy symptoms, local estrogen therapy should only be initiated for symptoms that adversely affect quality of life.
  • Blissel 50 micrograms/g vaginal gel must not be combined with estrogen preparations for systemic treatment, as there are no studies of safety and risks with estrogen concentrations attained in combination treatment.
  • Intravaginal applicator may cause minor local trauma, especially in women with serious vaginal atrophy.
  • Before estriol treatment is initiated or reinstituted, a complete personal and family medical history should be taken. Physical (including pelvic and breast) examination should be guided by this and by the contraindications and warnings for use.

Please refer to the Summary of Product Characteristics before prescribing.1

1. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.

Common (1/100 to <1/10) and (1/1000 to <1/100) undesirable effects1


Date of preparation: February 2026 Item code: UK-BLS-671